Bismuth arsphenamine sulphonate is an arsphenamine synthetic devised by Prof. G. W. Raiziss,1 having, according to the originator, an arsenical content of from 12 to 15 per cent and a bismuth content of from 23 to 25 per cent. The clinical study of this preparation in the treatment for syphilis was begun by Chambers and one of us (J. H. S.) in 1925, and two years' observation of its effects was reported by them in June, 1927.2 The following report includes a summary of three more years' experience with the use of the drug in clinical practice, the results of a reexamination of 94 of the original 204 patients, and a resume of the literature, including the 6 papers by other authors that have appeared since the original report by Chambers and one of us.1 This presentation does not deal in finalities and suffers inevitably from the
STOKES JH, MILLER TH, BEERMAN H. AN APPRAISAL OF THE NEWEST ARSPHENAMINE SYNTHETIC, BISMARSEN, IN THE TREATMENT FOR SYPHILIS: BASED ON SEVEN THOUSAND SIX HUNDRED AND SIXTY-SIX INJECTIONS IN THREE HUNDRED AND FORTY-ONE CASES DURING FIVE YEARS. Arch Derm Syphilol. 1931;23(4):624–643. doi:10.1001/archderm.1931.03880220026003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: